Abstract
Synergy between yttrium-90 (90Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI < 1 denoting synergy and CI > 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with 90Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with 90Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with 90Y radioembolization for treatment of liver cancer.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / therapy*
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cell Survival / radiation effects
-
Chemoradiotherapy / methods
-
Cholangiocarcinoma / pathology
-
Cholangiocarcinoma / therapy*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Dose-Response Relationship, Drug
-
Dose-Response Relationship, Radiation
-
Drug Synergism
-
Gemcitabine
-
Humans
-
Niacinamide / administration & dosage
-
Niacinamide / analogs & derivatives*
-
Organoplatinum Compounds / administration & dosage*
-
Paclitaxel / administration & dosage*
-
Phenylurea Compounds / administration & dosage*
-
Pyridines / administration & dosage*
-
Radiation Tolerance / drug effects
-
Radiopharmaceuticals / administration & dosage
-
Sorafenib
-
Yttrium Radioisotopes / therapeutic use*
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Phenylurea Compounds
-
Pyridines
-
Radiopharmaceuticals
-
Yttrium Radioisotopes
-
oxiplatin
-
Deoxycytidine
-
Niacinamide
-
Sorafenib
-
Paclitaxel
-
Gemcitabine